Them.Ns
Themis Bioscience Limited (THEM.NS) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Business. Themis Bioscience Limited (THEM.NS) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of autoimmune and inflammatory diseases.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Themis Bioscience Limited (THEM.NS) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Themis Bioscience maintains a conservative capital structure with a debt-to-equity ratio of 0.21, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.95, suggesting it has sufficient short-term assets to cover its liabilities, though not with a large buffer. Free cash flow stands at INR 197.33 million, which supports operational flexibility and potential reinvestment.
In terms of profitability, Themis Bioscience reports a return on equity (ROE) of 7.41% and a return on assets (ROA) of 5.07%. These figures are below the industry median for ROE and ROA in the Pharmaceuticals sector, indicating that the company is generating returns that are in line with, but not outperforming, its peers.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the Indian pharmaceutical market.
Looking ahead, Themis Bioscience is projected to experience a modest growth trajectory, with revenue expected to increase by 4.5% in the current fiscal year and 3.2% in the following year. This growth is driven by the continued commercialization of its flagship product, Tovilimab, and the potential for new product launches.
The company faces several risk factors, including regulatory challenges and the potential for dilution. The risk assessment indicates a low probability of dilution in the near term, with no significant dilution sources identified in recent filings. However, the company's net cash position is negative after subtracting total debt, which could impact its ability to fund operations without external financing.
Recent events include the filing of the annual report for FY2023, which provides an updated overview of the company's financial performance and strategic initiatives. The report highlights ongoing clinical trials and the expansion of the sales force to support market penetration.
- Themis Bioscience maintains a conservative capital structure with a low debt-to-equity ratio of 0.21.
- The company's ROE of 7.41% and ROA of 5.07% are in line with industry medians but do not outperform.
- Revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- The company is projected to experience modest revenue growth of 4.5% in the current fiscal year and 3.2% in the following year.
- The risk of dilution is currently low, but the company's net cash position is negative after subtracting total debt.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- THEM.NS Market data — financials · 2026-05-29
Ownership & reference
Leadership
- Dinesh Shantibhai PatelExecutive Chairman of the Board